CANbridge Pharmaceuticals Inc.
HKEX:1228.HK
0.295 (HKD) • At close September 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 29.91 | 29.91 | 21.526 | 21.526 | 22.122 | 22.122 | 17.364 | 17.364 | 9.485 | 9.485 | 5.637 | 6.555 | 5.044 | 5.044 | 1.202 | 0.742 |
| Cost of Revenue
| 11.167 | 11.167 | 8.187 | 8.187 | 8.759 | 8.759 | 6.281 | 6.281 | 3.516 | 3.516 | 2.462 | 2.891 | 2.051 | 2.051 | 0.766 | 0.287 |
| Gross Profit
| 18.744 | 18.744 | 13.339 | 13.339 | 13.364 | 13.364 | 11.084 | 11.084 | 5.969 | 5.969 | 3.175 | 3.664 | 2.994 | 2.994 | 0.436 | 0.455 |
| Gross Profit Ratio
| 0.627 | 0.627 | 0.62 | 0.62 | 0.604 | 0.604 | 0.638 | 0.638 | 0.629 | 0.629 | 0.563 | 0.559 | 0.593 | 0.593 | 0.363 | 0.613 |
| Reseach & Development Expenses
| 57.118 | 57.118 | 71.488 | 71.488 | 76.457 | 76.457 | 79.13 | 79.13 | 76.411 | 76.411 | 207.836 | 67.001 | 36.879 | 36.879 | 27.47 | 8.414 |
| General & Administrative Expenses
| 20.822 | 20.822 | 24.094 | 24.094 | 26.641 | 26.641 | 27.813 | 27.813 | 46.295 | 46.295 | 32.726 | 20.202 | 24.19 | 24.19 | 15.088 | 14.249 |
| Selling & Marketing Expenses
| 22.669 | 22.669 | 19.167 | 19.167 | 22.078 | 22.078 | 21.313 | 21.313 | 27.99 | 27.99 | 24.2 | 20.568 | 17.304 | 17.304 | 9.785 | 6.616 |
| SG&A
| 43.49 | 43.49 | 43.261 | 43.261 | 48.719 | 48.719 | 49.126 | 49.126 | 74.285 | 74.285 | 56.926 | 40.77 | 41.493 | 41.493 | 24.873 | 20.865 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 102.325 | 102.325 | 120.19 | 120.19 | 130.351 | 130.351 | 134.349 | 134.349 | 372.913 | 372.913 | 233.236 | 116.248 | 347.048 | 347.048 | 26.096 | 129.899 |
| Operating Income
| -81.864 | -81.864 | -101.41 | -101.41 | -111.813 | -111.813 | -117.172 | -117.172 | -144.727 | -144.727 | -261.587 | -104.107 | -75.379 | -75.379 | -51.907 | -28.824 |
| Operating Income Ratio
| -2.737 | -2.737 | -4.711 | -4.711 | -5.054 | -5.054 | -6.748 | -6.748 | -15.259 | -15.259 | -46.405 | -15.882 | -14.944 | -14.944 | -43.184 | -38.846 |
| Total Other Income Expenses Net
| 1.526 | 1.526 | -7.671 | -7.671 | -5.419 | -5.419 | -7.334 | -7.334 | -221.675 | -221.675 | 29.747 | -8.256 | -269.278 | -269.278 | 25.705 | -101.704 |
| Income Before Tax
| -80.338 | -80.338 | -109.081 | -109.081 | -117.232 | -117.232 | -124.506 | -124.506 | -366.402 | -366.402 | -231.84 | -112.363 | -344.657 | -344.657 | -26.202 | -130.528 |
| Income Before Tax Ratio
| -2.686 | -2.686 | -5.068 | -5.068 | -5.299 | -5.299 | -7.17 | -7.17 | -38.632 | -38.632 | -41.128 | -17.142 | -68.33 | -68.33 | -21.799 | -175.914 |
| Income Tax Expense
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income
| -80.338 | -80.338 | -109.081 | -109.081 | -117.232 | -117.232 | -124.506 | -124.506 | -366.402 | -366.402 | -231.84 | -112.363 | -344.657 | -344.657 | -26.202 | -130.528 |
| Net Income Ratio
| -2.686 | -2.686 | -5.068 | -5.068 | -5.299 | -5.299 | -7.17 | -7.17 | -38.632 | -38.632 | -41.128 | -17.142 | -68.33 | -68.33 | -21.799 | -175.914 |
| EPS
| -0.19 | -0.19 | -0.26 | -0.26 | -0.28 | -0.28 | -0.29 | -0.29 | -3.19 | -3.19 | -3.15 | -1.53 | -5.02 | -5.02 | -0.38 | -1.907 |
| EPS Diluted
| -0.19 | -0.19 | -0.26 | -0.26 | -0.28 | -0.28 | -0.29 | -0.29 | -3.19 | -3.19 | -3.15 | -1.53 | -5.02 | -5.02 | -0.38 | -1.905 |
| EBITDA
| -78.569 | -78.569 | -98.793 | -98.793 | -109.46 | -109.46 | -114.962 | -114.962 | -142.57 | -142.57 | -259.894 | -101.072 | -69.72 | -69.72 | -49.204 | -28.485 |
| EBITDA Ratio
| -2.627 | -2.627 | -4.59 | -4.59 | -4.948 | -4.948 | -6.621 | -6.621 | -15.032 | -15.032 | -46.105 | -15.419 | -13.822 | -13.822 | -40.935 | -38.389 |